Literature DB >> 32515221

RNA N-6-methyladenosine enzymes and resistance of cancer cells to chemotherapy and radiotherapy.

Meiyi Xiang1, Wensu Liu1, Wei Tian1, Abin You1, Dajun Deng1.   

Abstract

Aim: As one of the early adaptive mechanisms by which cells respond to environmental changes, RNA modification appears to be a very promising target for cancer treatment.
Results: RNA modifications are currently a hot topic in epigenetic research. Emerging experimental studies show that expression alterations of multiple m6A enzymes, including demethylase FTO, methyltransferase METTL3 and WTAP, mediate the development of resistance of cancer cells to various treatments. A set of small molecular chemical drugs targeted to these m6A enzymes are under development. Intervention of RNA m6A methylation is a possible therapeutic strategy to overcome drug resistance. Conclusions: RNA m6A methylation may play a crucial role in drug resistance development and intervention in cancer cells.

Entities:  

Keywords:  ALKBH5; FTO; METTL14; METTL3; RNA methylation; WTAP; cancer; drug resistance; m6A

Year:  2020        PMID: 32515221     DOI: 10.2217/epi-2019-0358

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  14 in total

1.  m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer.

Authors:  Congjun Zhang; Shuangyan Ou; Yuan Zhou; Pei Liu; Peiying Zhang; Ziqian Li; Ruocai Xu; Yuqiang Li
Journal:  Front Oncol       Date:  2021-08-11       Impact factor: 6.244

2.  TTC22 promotes m6A-mediated WTAP expression and colon cancer metastasis in an RPL4 binding-dependent pattern.

Authors:  Abin You; Wei Tian; Hongfan Yuan; Liankun Gu; Jing Zhou; Dajun Deng
Journal:  Oncogene       Date:  2022-07-07       Impact factor: 8.756

3.  The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors.

Authors:  Vera Miranda-Gonçalves; João Lobo; Rui Henrique; Carmen Jerónimo; Catarina Guimarães-Teixeira; Daniela Barros-Silva; Rita Guimarães; Mariana Cantante; Isaac Braga; Joaquina Maurício; Christoph Oing; Friedemann Honecker; Daniel Nettersheim; Leendert H J Looijenga
Journal:  J Exp Clin Cancer Res       Date:  2021-08-25

4.  Mettl14-mediated m6A modification modulates neuron apoptosis during the repair of spinal cord injury by regulating the transformation from pri-mir-375 to miR-375.

Authors:  Haoyu Wang; Jing Yuan; Xiaoqian Dang; Zhibin Shi; Wenrui Ban; Dong Ma
Journal:  Cell Biosci       Date:  2021-03-11       Impact factor: 7.133

5.  FTO Gene Polymorphisms Contribute to the Predisposition and Radiotherapy Efficiency of Nasopharyngeal Carcinoma.

Authors:  Feng Xiao; Jianrong Zhou
Journal:  Pharmgenomics Pers Med       Date:  2021-09-28

6.  RNA N6-methyladenosine: a new player in autophagy-mediated anti-cancer drug resistance.

Authors:  Arumugam Paramasivam; Jayaseelan Vijayashree Priyadharsini
Journal:  Br J Cancer       Date:  2021-03-15       Impact factor: 7.640

Review 7.  Methylation Landscape: Targeting Writer or Eraser to Discover Anti-Cancer Drug.

Authors:  Wen-Min Zhou; Bin Liu; Amin Shavandi; Lu Li; Hang Song; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

8.  Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation.

Authors:  Nan Ding; Abin You; Wei Tian; Liankun Gu; Dajun Deng
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580

Review 9.  The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications.

Authors:  Sha Qin; Yitao Mao; Haofan Wang; Yingxing Duan; Luqing Zhao
Journal:  Int J Biol Sci       Date:  2021-06-26       Impact factor: 6.580

10.  G9a Regulates Cell Sensitivity to Radiotherapy via Histone H3 Lysine 9 Trimethylation and CCDC8 in Lung Cancer.

Authors:  Yunfen Li; Zhengting Chen; Ke Cao; Lan Zhang; Yuhui Ma; Shuhui Yu; Hanyu Jin; Xiaoling Liu; Wenhui Li
Journal:  Onco Targets Ther       Date:  2021-06-10       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.